25 November 2017
News and Views
Links and Services
The latest Journal of Clinical Oncology identifies progression-free survival as an end point for assessing efficacy of overall survival in advanced colorectal cancer.
The traditional end point for assessing efficacy of first-line chemotherapies for advanced cancer
Email this page to a colleague
GastroHep.com is a Blackwell Publishing registered trademark
© 2017 Wiley-Blackwell and GastroHep.com and contributors